Differentiated thyroid cancer (DTC) largely resists standard immune checkpoint immunotherapy, leaving patients with limited options. This Japanese study examined immune cells in tumor tissue and blood from 12 DTC patients and 12 benign goiter controls. Researchers found that effector regulatory T-cells — immune suppressors that help tumors hide from attack — were significantly elevated and activated in DTC tumors. More striking, over 92% of these suppressive cells expressed the surface receptor CCR4 in both tumor tissue and circulating blood. CCR4 is the target of mogamulizumab, an already-approved anti-cancer antibody. The findings suggest that deploying mogamulizumab to deplete these suppressive T-cells could unmask thyroid tumors to immune attack, potentially offering a new immunotherapy avenue where checkpoint inhibitors have so far failed.
